5Pastor A, Menendex R, Cremades MJ,et a.1 Diagnostic value of sce CEA and CYFRA 21 .1 in lung cancer[J]. Abayseian analysis Eur Respir J, 1997, 10(3) : 603 - 609.
6Niwa Y, Kisnimoto H, Shimokata K. Carcinomatous and tuberculors pleural effusions. Comparison of tumor markers[J].Chest, 1985,87(3): 351 - 355.
7Yilmaz Turay U,Yildirim Z, Turkoz Y, et al. Use of pleural fluid C- reactive protein in diagnosis of pleural effusion [ J ] .Respir Med,2000,94(5) :432.
8Castano Vidriales JL,Araores Antequera C. Use of pleural fluid Creactive protein in laboratory diagnosis of pleural effusions [J ].Eur J Med, 1992,1:201.
9张波，肿瘤研究与临床，1996年，8卷，73页
10Baughman R P，J Lab Clin Med，1991年，118卷，118期，326页
7Porcel JM, Vives M, Esquerda A, et al. Use of a panel of tumor markers(carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions [ J ] . Chest, 2004, 126 ( 6 ) : 1757-1763.
8Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging [J] .Chest, 2004, 125 (2):489-493.
9Gupta NC, Rogers JS, Graeber GM, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion [ J ]. Chest, 2002, 122 (6) : 1918-1924.
10Kilie D, Akay H, Kavukqu S, et al. Management of recurrent malignant pleural effusion with chemical pleurodesis [ J ]. Surg Today, 2005,35 (8) :634 -638.
